JG
JNCE

Jefferies Group’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Jefferies Group’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$309K Buy
+132,115
New +$468K ﹤0.01% 1213
2019
Q4 		– Sell
-13,557
Closed -$45K – 3139
2019
Q3 		$45K Buy
+13,557
New +$54.3K ﹤0.01% 2586

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Jefferies Group's JNCE Position: Q3 2022 in Review

Jefferies Group opened a new position in Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2022: 132,115 shares worth $309K. The stake represents ﹤0.01% of the portfolio and ranks #1213 among its holdings. This is a return to the name: Jefferies Group previously reported a position in JNCE as recently as Q3 2019.

Jefferies Group first reported a position in JNCE in Q3 2019 and has held it in 2 quarters since. 102 funds tracked by Wall St. Rank hold JNCE as of Q3 2022.

  • Jefferies Group held 132,115 shares of Jounce Therapeutics, Inc. Common Stock worth $309K as of Q3 2022.
  • Jounce Therapeutics, Inc. Common Stock was a new Jefferies Group position in Q3 2022.
  • Jounce Therapeutics, Inc. Common Stock made up ﹤0.01% of Jefferies Group's portfolio in Q3 2022, its #1213 holding.
  • Jefferies Group first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2019 and has held it in 2 quarters since.
  • 102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.